Inhibition of carboxyethylphosphoramide mustard formation from 4-hydroxycyclophosphamide by carmustine

AAPS PharmSci

Volumn 1, Issue 3, 1999, Pages 58-65

  Ren, Song ^a   Slattery, John T ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Cyclophosphamide carmustine ALDH1 4 hydroxycyclophosphamide alkylator

Indexed keywords

EID: 33947162534     PISSN: 15221059     EISSN: None     Source Type: Journal    
DOI: 10.1208/ps010314     Document Type: Article

References (21)

1. Ren, S., Yang, J.-S., Kalhorn, T. F., and Slattery, J. T. Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver microsomes. Cancer Res., 57: 4229-4235, 1997.
2. Chang, T. K. H., Yu, L., Goldstein, J. A., and Waxman, D. J. Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-K-m catalysts of cyclophosphamide and ifosfamide activation. Pharmacogenetics, 7: 211-221, 1997.
3. Dockham, P. A., Lee, M.-O., and Sladek, N. E. Identification of human liver aldehyde dehydrogenases that catalyze the oxidation of aldophosphamide and retinaldehyde. Biochem. Pharmacol., 43: 2453-2469, 1992.
4. Parekh, H. K. and Sladek, N. E. NADPH-dependent enzyme-catalyzed reduction of aldophosphamide, the pivotal metabolite of cyclophosphamide. Biochem. Pharmacol., 46: 1043-1052, 1993.
5. Sladek, N. E. Metabolism and pharmacokinetics of cyclophosphamide and related oxazaphosphorines. In: G. Powis (ed.) Anticancer Drugs: Reactive Metabolism and Drug Interactions, pp. 79-156. New York: Pergamon Press Ltd., 1994.
6. Devita, V. T., Hellman, S., and Rosenberg, S. A. Cancer: Principles and Practice of Oncology. Philadelphia: Lippincott, 1985.
7. Colvin, M. and Brundrett, R. Chemical decomposition of chloroethylnitrosoureas. In: A. W. Prestakyo, S. T. Crooke, S. K. Baker, and P. S. Schein (eds.), Nitrosoureas, pp. 43-49. New York: Academic Press, 1981.
8. Ludlum, D. B. and Tong, W. P. Modification of DNA and RNA bases. In: A. W. Prestakyo, S. T. Crooke, S. K. Baker, and P. S. Schein (eds.), Nitrosoureas, pp. 85-94. New York: Academic Press, 1981.
9. Ayash, L. J., Hunt, M., Antman, K., Nadler, L., Wheeler, C., Takvorian, T., Elias, A., Antin, J. H., Greenough, T., and Eder, J. P. Hepatic venoocclusive disease in autologous bone marrow transplantation of solid tumors and lymphomas. J Clin. Oncol., 8: 1699-1706, 1990.
10. Nagasawa, H. T., Elberling, J. A., Good, D. J., and Shirota, F. N. Latent alkyl isocyanates as inhibitors of aldehyde dehydrogenase in vivo. J Med. Chem., 37: 4222-4226, 1994.
11. Takamizawa, A., Matsumoto, S., Iwata, T., Tochino, Y., Katagiri, K., and Yamaguchi, K. Studies on cyclophosphamide metabolites and their related compounds. II. Preparation of an active species of cyclophosphamide and related compounds. J Med. Chem., 18: 376-83, 1975.
12. Bradford, M. A. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72: 248-254, 1976.
13. Yoshida, A., Dave, V., Ward, R. J., and Peters, T. J. Cytosolic aldehyde dehydrogenase (ALDH1) variants found in alcohol flushers. Ann. Hum. Genet., 53: 1-7, 1989.
14. Ren, S., Kalhorn, T. F., McDonald, G. B., Anasetti, C., Appelbaum, F. R., and Slattery, J. T. Pharmacokinetics of Cyclophosphamide and its Metabolites in Bone Marrow Transplantation Patients. Clin. Pharmacol. Ther., 64: 289-301, 1998.
15. Segel, I. H. Enzyme Kinetics. New York: John Wiley & Sons, 1975.
16. Ren, S., Kalhorn, T. F., and Slattery, J. T. Inhibition of human aldehyde dehydrogenase 1 by the 4-hydroxycyclophosphamide degradation product acrolein. Drug Met. Dispos., In press.
17. DeLeve, L. D. Cellular target of cyclophosphamide toxicity in the murine liver: Role of glutathione and site of metabolic activation. Hepatology, 24: 830-837, 1996.
18. Alarcon, R. A. Studies on the in vivo formation of acrolein: 3-hydroxypropylmercapturic acid as an index of cyclophosphamide (NSC-26271) activation. Cancer Treat. Rep., 60: 327-335, 1976.
19. Frischer, H. and Ahmad, T. Consequences of erythrocytic glutathione reductase deficiency. J Lab Clin. Med., 109: 583-588, 1987.
20. Frischer, H., Kennedy, E. J., Chigurupati, R., and Sivarajan, M. Glutathione, cell proliferation, and 1,3-bis-(2-chloroethyl)-1-nitrosourea in K562 leukemia. J Clin. Invest., 92: 2761-2767, 1993.
21. Chang, T. K. H., Yu, L., Maurel, P., and Waxman, D. J. Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: Response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Res., 57: 1946-1954, 1997.